A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Jun 2017 Planned number of patients changed from 20 to 50.
- 09 Jun 2017 Planned End Date changed from 30 Nov 2018 to 31 Oct 2020.
- 14 Oct 2016 Status changed from not yet recruiting to recruiting.